Clinical trial
A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination With Pomalidomide, Carfilzomib and Dexamethasone Among High Risk Relapsed/ Refractory Multiple Myeloma Patients
NCT03104270 is registered in ClinicalTrials.gov with Oncotherapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination With Pomalidomide, Carfilzomib and Dexamethasone Among High Risk Relapsed/ Refractory Multiple Myeloma Patients
- Lead sponsor
- Oncotherapeutics
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- March 13, 2017
- Completion date
- January 23, 2020
- Enrollment
- 13 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.